Akebia Therapeutics Inc (AKBA)
1.845
+0.16
(+9.17%)
USD |
NASDAQ |
Nov 04, 16:00
1.85
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Gross Profit Margin (Quarterly): 60.94% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 60.94% |
| March 31, 2024 | 64.41% |
| December 31, 2023 | 66.79% |
| September 30, 2023 | 57.17% |
| June 30, 2023 | 69.34% |
| March 31, 2023 | 49.53% |
| December 31, 2022 | |
| September 30, 2022 | 21.42% |
| June 30, 2022 | 85.28% |
| March 31, 2022 | 49.20% |
| December 31, 2021 | 17.42% |
| September 30, 2021 | 67.30% |
| Date | Value |
|---|---|
| June 30, 2021 | 0.79% |
| March 31, 2021 | 33.84% |
| December 31, 2020 | -13.86% |
| September 30, 2020 | 49.41% |
| June 30, 2020 | -93.71% |
| March 31, 2020 | 68.68% |
| December 31, 2019 | 45.16% |
| September 30, 2019 | 58.40% |
| June 30, 2019 | 62.63% |
| March 31, 2019 | 56.99% |
| December 31, 2018 | 87.02% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-93.71%
Minimum
Jun 2020
85.28%
Maximum
Jun 2022
38.84%
Average
49.47%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 98.43% |
| Bioventus Inc | 68.54% |
| Eli Lilly and Co | 81.02% |
| NovaBay Pharmaceuticals Inc | 66.33% |
| Palatin Technologies Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -17.19% |
| Return on Invested Capital | -671.1% |
| Profit Margin (Quarterly) | -19.66% |
| Operating Margin (Quarterly) | -19.99% |
| Return on Net Operating Assets | -24.55% |